Peripheral ischemic limb necrosis in septic shock patient: A case report.

Medicine (Baltimore)Sep 11, 2026
Case ReportGeneral SurgeryPlastic SurgeryInfectious DiseasesOpen access

Ji Woong Ho, Young-Keun Lee

✦ AI-curated · Sources linked

Case in brief

A 62-year-old male presented with dyspnea, weakness, and skin color changes, diagnosed with sepsis and disseminated intravascular coagulation (DIC). He developed ischemic limb necrosis, confirmed by laboratory results and blood cultures positive for S suis. After 49 days of intensive care treatment, multiple amputations were performed, and a free ALT flap was later created for a soft tissue defect on the left heel.

Diagnostic / clinical pearl

Peripheral ischemic limb necrosis should be considered in septic shock patients with DIC, especially those receiving vasopressors.

Why it matters

Surgical intervention timing is critical; it should occur only after necrosis is well-demarcated and in the context of improving DIC and vasopressor management.

Source

PubMed · PMID 42736789Free full text on PubMed Central

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.